Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Predicting Development of Diabetes Mellitus in Patients Undergoing Allogeneic Stem Cell Transplant

15. juli 2019 oppdatert av: Brian Engelhardt, MD, Vanderbilt-Ingram Cancer Center

Metabolic and CD4+ T Cell Dysregulation in Post-Transplant Diabetes Mellitus

This clinical trial studies the physiology and immunology of new-onset post-transplant diabetes mellitus in patients undergoing allogeneic stem cell transplantation. Oral glucose tolerance testing (OGTT), euglycemic hyperinsulinemic clamps, and immune assays will be used to define the mechanisms associated with abnormal glucose homeostasis following stem cell transplantation. Information from this clinical trial could be used to develop standardized screening procedures or to develop optimal treatment strategies for patients developing post-transplant diabetes mellitus.

Studieoversikt

Status

Avsluttet

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

PRIMARY OBJECTIVES:

I. To determine whether pre-transplant insulin resistance predicts for the development of new onset post-transplant diabetes mellitus (PTDM) in individuals without diabetes undergoing matched related donor (MRD) hematopoietic stem cell transplant (HCT).

II. To define the role of circulating tissue-specific Th1 cells in the development of PTDM.

III. To characterize the phenotype and function of circulating tissue-specific regulatory T cells (Tregs) in HCT recipients with or without PTDM.

OUTLINE:

Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.

Studietype

Intervensjonell

Registrering (Faktiske)

22

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

  • Forente stater
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
        • Vanderbilt-Ingram Cancer Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Patients undergoing MRD allogeneic HCT
  • DONOR: Donors undergoing stem cell collection for match related allogeneic stem cell transplant

Exclusion Criteria:

  • Patients who have not received an allogeneic HCT
  • Recent or current history of diabetes mellitus, defined as:1) diabetes therapy within 6 months of enrollment, or 2) fasting blood glucose at "pre-admit" (screening) visit >= 126 mg/dL
  • Pregnancy or breastfeeding
  • Unrelated donor, umbilical cord blood, mismatched, or haploidentical transplants
  • Patients receiving T cell depletion or thymoglobulin as part of their transplant
  • Patients on established, chronic corticosteroid therapy (> 5 mg /day of prednisone or prednisone equivalent) prior to transplant; established, chronic corticosteroid therapy is defined as daily dosing of > 5 mg/day of prednisone or prednisone equivalent for at least 2 weeks prior to the start of conditioning/chemotherapy or plans to continue pre-transplant corticosteroids (> 5 mg/day of prednisone or prednisone equivalent) indefinitely after transplantation
  • Inability to give informed consent
  • Any condition which, in the opinion of the investigator, might interfere with study objective
  • Any reason which, in the opinion of the investigator, adds additional risk to the patient
  • DONOR: Individuals not donating stem cells
  • DONOR: Pregnancy or breastfeeding
  • DONOR: Inability to give informed consent
  • DONOR: Any condition which, in the opinion of the investigator, might interfere with study objective

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Diagnostic (OGTT, euglycemic hyperinsulinemic clamp)
Patients undergo OGTT and a standard 2-step euglycemic hyperinsulinemic clamp procedure prior to HCT. Patients then undergo repeat OGTT and a 2-step euglycemic hyperinsulinemic clamp procedure once after HCT between days 90-100.
Annen: laboratoriebiomarkøranalyse
Korrelative studier
Fremgangsmåte: assessment of therapy complications
During OGTT 75gm of glucose will be given followed by phlebotomy
Fremgangsmåte: assessment of therapy complications
During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pre-transplant peripheral insulin sensitivity and glucose disposal as defined by the peripheral insulin sensitivity index among patients who do or do not go on to develop PTDM
Tidsramme: Up to 21 days pre-transplant
Patients will be followed for 100 days after transplant for development of diabetes. Wilcoxon rank sum test will be applied to compare the population mean difference between these two groups. Multivariable logistic regression will evaluate whether the peripheral insulin sensitivity index is an independent predictor of PTDM after adjusting for the following covariates: fasting C-peptide level, conditioning (ablative vs. reduced intensity), or acute graft-versus-host disease (GVHD) requiring steroids. The estimated odds ratio (OR) and 95% confidence interval of the OR will be provided to measure the effect of the association.
Up to 21 days pre-transplant
Ratio of circulating, gut-homing (alpha4beta7+) Th1 subsets pre-transplant with the development of PTDM after HCT
Tidsramme: Up to day 100 after transplant
Wilcoxon rank sum test will be applied to compare the mean difference between these two groups.
Up to day 100 after transplant
Expression of Helios or glycoprotein A repetitions predominant in alpha4beta7+Foxp3+ Tregs versus alpha4beta7+Foxp3- conventional T cells
Tidsramme: Up to day 100 after transplant
Wilcoxon rank sum test or two-sample t-test will be applied to compare the mean difference between two groups. Data will be presented using means and standard deviations for continuous variables, as well as percentage and frequency for categorical variables.
Up to day 100 after transplant

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in hepatic insulin sensitivity among patients with or without established PTDM
Tidsramme: Baseline to day 90 after transplant
Comparison between two independent groups, e.g., with or without PTDM, will be carried out using either two-sample t-test or Wilcoxon rank sum test for continuous variables and Chi-square test or Fisher's exact test for categorical variables.
Baseline to day 90 after transplant
Changes in peripheral insulin sensitivity among patients with or without established PTDM
Tidsramme: Baseline to day 90 after transplant
Comparison between two independent groups, e.g., with or without PTDM, will be carried out using either two-sample t-test or Wilcoxon rank sum test for continuous variables and Chi-square test or Fisher's exact test for categorical variables.
Baseline to day 90 after transplant
Changes in OGTT results among patients with or without established PTDM
Tidsramme: Baseline to day 90 after transplant
Comparison between two independent groups, e.g., with or without PTDM, will be carried out using either two-sample t-test or Wilcoxon rank sum test for continuous variables and Chi-square test or Fisher's exact test for categorical variables.
Baseline to day 90 after transplant
Changes in hepatic insulin sensitivity in the entire cohort
Tidsramme: Baseline to day 90 after transplant
For the comparison of the changes between baseline and day+90 after transplant in the entire cohort, the mean difference will be compared with paired Student's t-test or Wilcoxon signed rank test for continuous variables and a McNemar's test for categorical variables.
Baseline to day 90 after transplant
Changes in peripheral insulin sensitivity in the entire cohort
Tidsramme: Baseline to day 90 after transplant
For the comparison of the changes between baseline and day+90 after transplant in the entire cohort, the mean difference will be compared with paired Student's t-test or Wilcoxon signed rank test for continuous variables and a McNemar's test for categorical variables.
Baseline to day 90 after transplant
Changes in OGTT results among patients in the entire cohort
Tidsramme: Baseline to day 90 after transplant
For the comparison of the changes between baseline and day+90 after transplant in the entire cohort, the mean difference will be compared with paired Student's t-test or Wilcoxon signed rank test for continuous variables and a McNemar's test for categorical variables.
Baseline to day 90 after transplant
Changes in hepatic insulin sensitivity among different groups
Tidsramme: Baseline to day 90 after transplant
To compare the differences between baseline (pre-transplant) and day +90 test results among various groups, linear mixed model will be applied to continuous outcomes (i.e., peripheral insulin sensitivity and hepatic glucose production) and generalized linear mixed model to noncontinuous outcomes (i.e., OGTT results). Groups of interest will be created by stratifying patients based on PTDM, conditioning regimen (ablative vs. reduced intensity) or acute GVHD treated with steroids.
Baseline to day 90 after transplant
Changes in peripheral insulin sensitivity among different groups
Tidsramme: Baseline to day 90 after transplant
To compare the differences between baseline (pre-transplant) and day +90 test results among various groups, linear mixed model will be applied to continuous outcomes (i.e., peripheral insulin sensitivity and hepatic glucose production) and generalized linear mixed model to noncontinuous outcomes (i.e., OGTT results). Groups of interest will be created by stratifying patients based on PTDM, conditioning regimen (ablative vs. reduced intensity) or acute GVHD treated with steroids.
Baseline to day 90 after transplant
Changes in OGTT results among different groups
Tidsramme: Baseline to day 90 after transplant
To compare the differences between baseline (pre-transplant) and day +90 test results among various groups, linear mixed model will be applied to continuous outcomes (i.e., peripheral insulin sensitivity and hepatic glucose production) and generalized linear mixed model to noncontinuous outcomes (i.e., OGTT results). Groups of interest will be created by stratifying patients based on PTDM, conditioning regimen (ablative vs. reduced intensity) or acute GVHD treated with steroids.
Baseline to day 90 after transplant
Ability of pre-transplant or post-transplant tissue-specific Tregs or Th1 cells to predict the development of PTDM
Tidsramme: Up to day 100 after transplant
The comparison between independent groups, e.g., with or without PTDM or the three OGTT groups (normal, impaired glucose tolerance, or diabetic), will be carried out using either Wilcoxon rank sum test or Kruskal-Wallis test, respectively.
Up to day 100 after transplant
Insulin clamp indices
Tidsramme: Up to day 100 after transplant
Spearman correlation will be used to evaluate the correlation between insulin clamp indices and Th1/Treg frequencies.
Up to day 100 after transplant
Th1/Treg frequencies
Tidsramme: Up to day 100 after transplant
Spearman correlation will be used to evaluate the correlation between insulin clamp indices and Th1/Treg frequencies.
Up to day 100 after transplant
Pre-HCT Th1 and Treg tissue-specific subsets
Tidsramme: Up to 100 days pre-transplant
Spearman correlation will evaluate the association between pre-HCT Th1 and Treg tissue-specific subsets with post-HCT donor derived Th1 and Treg.
Up to 100 days pre-transplant
Ability of alpha4beta7+ Tregs from patients with or without PTDM in suppressing the proliferation of allogeneic T cells
Tidsramme: Up to day 90 after transplant
Wilcoxon rank sum test or two-sample t-test will be applied to compare the mean difference between two groups. Data will be presented using means and standard deviations for continuous variables, as well as percentage and frequency for categorical variables. Investigations for outliers and assumptions for statistical analysis, e.g., normality and homoscedasticity will be made for the parametric test such as t-test and mixed model. If necessary, data will be transformed utilizing appropriate transformations such as the log or square root.
Up to day 90 after transplant
Ability of effector T cells from patients with PTDM to be resistant to suppression from Tregs obtained from healthy individuals
Tidsramme: Up to day 100 after transplant
Wilcoxon rank sum test or two-sample t-test will be applied to compare the mean difference between two groups. Data will be presented using means and standard deviations for continuous variables, as well as percentage and frequency for categorical variables.
Up to day 100 after transplant
Post-HCT donor derived Th1 and Treg subsets
Tidsramme: Up to 100 days pre-transplant
Spearman correlation will evaluate the association between pre-HCT Th1 and Treg tissue-specific subsets with post-HCT donor derived Th1 and Treg.
Up to 100 days pre-transplant

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Vanderbilt-Ingram Cancer Center

Samarbeidspartnere

National Cancer Institute (NCI)

Etterforskere

  • Hovedetterforsker: Brian Engelhardt, Vanderbilt-Ingram Cancer Center

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

20. november 2014

Primær fullføring (Faktiske)

8. januar 2019

Studiet fullført (Faktiske)

8. januar 2019

Datoer for studieregistrering

Først innsendt

28. august 2014

Først innsendt som oppfylte QC-kriteriene

11. september 2014

Først lagt ut (Anslag)

15. september 2014

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. juli 2019

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. juli 2019

Sist bekreftet

1. juli 2019

Mer informasjon

Begreper knyttet til denne studien

Ytterligere relevante MeSH-vilkår

Andre studie-ID-numre

  • VICC BMT 1426
  • P30CA068485 (U.S. NIH-stipend/kontrakt)
  • NCI-2014-01250 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Sukkersyke

Kliniske studier på laboratoriebiomarkøranalyse

Søk i lignende forsøk

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

CROs by country

CROs in Togo

Forhold

Sjeldne sykdommer

Legemiddelintervensjoner

Kosttilskudd

Sponsor / samarbeidspartnere

Steder

3
Abonnere